Thermo Fisher Scientific Inc. $TMO Position Lowered by CreativeOne Wealth LLC

CreativeOne Wealth LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% during the 1st quarter, HoldingsChannel.com reports. The firm owned 6,525 shares of the medical research company’s stock after selling 306 shares during the quarter. CreativeOne Wealth LLC’s holdings in Thermo Fisher Scientific were worth $3,247,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter worth about $35,000. Finally, Navigoe LLC bought a new position in Thermo Fisher Scientific in the fourth quarter worth about $37,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $488.47 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $184.45 billion, a PE ratio of 28.25, a P/E/G ratio of 2.61 and a beta of 0.74. The company’s 50 day simple moving average is $448.63 and its 200 day simple moving average is $455.69.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of recent research reports. Hsbc Global Res cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. HSBC reaffirmed a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Raymond James Financial reaffirmed an “outperform” rating and set a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 10th. Finally, Wells Fargo & Company cut their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $593.00.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,896 shares of company stock worth $13,603,438 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.